Vir Biotechnology(NASDAQ) VIR

Vir Biotechnology, Inc. helps the body fight infections and cancer. These treatments target serious liver diseases and solid tumors. The company seeks to help patients with few treatment options.

Fighting Disease With Immune Power

• Hepatitis Delta Program: Combination of elebsiran and tobevibart in late-stage trials for chronic hepatitis delta, a serious liver infection.
• T-cell Engagers: Medicines designed to help the immune system find and attack prostate, breast, and lung cancer cells.
• Infectious Disease Research: Ongoing development of therapies for chronic hepatitis B, human immunodeficiency virus (HIV), and influenza A.
• Antibody Treatments: Specialized proteins used to treat or prevent viral infections, including work on next-generation COVID antibodies.

Expanding the Medical Toolkit

• Closed a global strategic collaboration with Astellas US LLC in 2026 to develop a treatment for prostate cancer.
• Completed enrollment for the entire ECLIPSE registrational program in 2026 to support potential approval for hepatitis delta treatments.
• Initiated new study groups in 2026 to test cancer therapies both alone and in combination with other medicines.
• Raised approximately $162.2 million through a public stock offering in Feb. 2026 to fund ongoing research and operations.

What Sets Vir Apart

The company uses a specialized platform to create masked T-cell engagers, which are molecules designed to activate the immune system specifically within tumors to reduce side effects. It maintains a broad network of partners and grant providers, including the Bill & Melinda Gates Foundation, to support its diverse pipeline.

A Look at the Books

• Total revenues reached $238.9 million for the three-month period ended June 30, 2026, up from $1.2 million in the same period of 2025.
• License and collaboration revenue was $238.9 million in the second quarter of 2026, primarily due to a $239.3 million upfront payment from Astellas.
• Net income was $80.1 million for the three-month period ended June 30, 2026, compared to a net loss of $111.0 million in 2025.
• Cash, cash equivalents, and investments totaled approximately $1.01 billion as of June 30, 2026.
• Research and development expenses rose to $135.3 million in the second quarter of 2026, up from $97.5 million in the prior year period.

Bottom Line

Vir Biotechnology has transitioned from an infectious disease specialist into a multi-program immunology company with late-stage trials in liver disease and oncology. Its significant cash reserves and major industry partnerships provide a foundation for advancing its clinical pipeline toward potential commercial use.